{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "BRL", "exchange": "SAO", "shortName": "ASCENDIS PHADRN", "longName": "Ascendis Pharma A/S", "messageBoardId": "finmb_39510693", "exchangeTimezoneName": "America/Sao_Paulo", "exchangeTimezoneShortName": "BRT", "gmtOffSetMilliseconds": -10800000, "market": "br_market", "esgPopulated": false, "regularMarketChangePercent": 0.0, "regularMarketPrice": 30.84, "marketState": "PREPRE", "fiftyTwoWeekHighChangePercent": -0.23814228, "fiftyTwoWeekLow": 0.0, "fiftyTwoWeekHigh": 40.48, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -55.51, "sharesOutstanding": 56215400, "bookValue": 2.974, "fiftyDayAverage": 32.2862, "fiftyDayAverageChange": -1.4462013, "fiftyDayAverageChangePercent": -0.04479317, "twoHundredDayAverage": 36.1249, "twoHundredDayAverageChange": -5.2849007, "twoHundredDayAverageChangePercent": -0.14629523, "marketCap": 26521659392, "priceToBook": 10.369872, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "priceHint": 2, "regularMarketChange": 0.0, "regularMarketTime": 1683313122, "regularMarketDayHigh": 0.0, "regularMarketDayRange": "0.0 - 0.0", "regularMarketDayLow": 0.0, "regularMarketVolume": 0, "regularMarketPreviousClose": 30.84, "bid": 30.36, "ask": 32.58, "fullExchangeName": "S\u00e3o Paulo", "financialCurrency": "EUR", "regularMarketOpen": 0.0, "averageDailyVolume3Month": 758, "averageDailyVolume10Day": 1986, "fiftyTwoWeekLowChange": 30.84, "fiftyTwoWeekRange": "0.0 - 40.48", "fiftyTwoWeekHighChange": -9.639999, "firstTradeDateMilliseconds": 1603198800000, "symbol": "A1SN34.SA"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Tuborg Boulevard 12", "city": "Hellerup", "zip": "2900", "country": "Denmark", "phone": "45 70 22 22 44", "website": "https://ascendispharma.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 \u00df/? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.", "fullTimeEmployees": 797, "companyOfficers": [{"maxAge": 1, "name": "Mr. Jan Moller Mikkelsen", "age": 62, "title": "Pres, CEO, Member of Exec. Board & Exec. Director", "yearBorn": 1960, "fiscalYear": 2022, "totalPay": {"raw": 0, "fmt": null, "longFmt": "0"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Scott T. Smith", "age": 48, "title": "CFO, Exec. VP & Member of Exec. Board", "yearBorn": 1974, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Lotte  Sonderbjerg", "age": 61, "title": "Exec. VP, Chief Admin. Officer & Member of the Exec. Board", "yearBorn": 1961, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Michael Wolff Jensen L.L.M.", "age": 51, "title": "Exec. VP, Chief Legal Officer & Member of the Exec. Board", "yearBorn": 1971, "fiscalYear": 2021, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Peter  Rasmussen", "age": 53, "title": "VP of Fin. & Principal Accounting Officer", "yearBorn": 1969, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Timothy J. Lee", "title": "Sr. Director of Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Flemming Steen Jensen", "age": 61, "title": "Exec. VP of Product Supply & Quality - Endocrinology Rare Diseases", "yearBorn": 1961, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Kennett  Sprogoe Ph.D.", "age": 43, "title": "Exec. VP and Head of Innovation & Research", "yearBorn": 1979, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Birgitte  Volck M.D., Ph.D.", "age": 60, "title": "Exec. VP and Head of Clinical Devel. & Medical Affairs - Endocrinology", "yearBorn": 1962, "fiscalYear": 2021, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Jens Sigurd Okkels Ph.D.", "age": 61, "title": "Exec. VP of Product Devel.", "yearBorn": 1961, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}